New Advances in Chemical Research in 2021. In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 166591-85-1, name is 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, introducing its new discovery. name: 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid
The invention belongs to the technical field of chemical medicine, relates to bridge piperazine derivative or its salt and its preparation method, and the states the bridge arch piperazine derivative or a salt thereof in the preparation in the treatment of diseases associated with the ROR gamma t use in the medicament. By experiment, the results display, of the bridge of the present invention can effectively inhibit the piperazine derivatives ROR gamma t protein receptor, regulating Th17 cell differentiation, inhibiting IL – 17 production, can be further used to treat ROR gamma t-mediated inflammation-related drug for the treatment of such diseases, especially suitable for the treatment of multiple sclerosis, rheumatoid arthritis, collagen induced arthritis, psoriasis, inflammatory bowel disease, encephalomyelitis, cloning disease, asthma, inflammation-related diseases such as cancer. (by machine translation)
One of the oldest and most widely used commercial enzyme inhibitors is aspirin, name: 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 166591-85-1
Reference：
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem